New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

Free PDF Access

Sign in to download PDF book and chapters

Free Resources

Related Titles

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "2. Priority Setting for Health-Related Investments: A Review of Methods." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

Page
21


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

TABLE 2.1 A Hypothetical Example of Multiattribute Accounting

	Criteria
Vaccine Candidates	Potential Lives Saved per Year	Potential Direct Economic Cost Saved per Year (dollars)	Potential Morbidity Averted	Vaccine Efficacy^a (percent)	Cost of Development ($ millions)	Time to Development (years)	Likelihood of Successful Development	Ease of Implementation	Cost of Production and Implementation
A	10,000	500,000	High	75	10	2–3	Good	Excellent	Moderate
B	15,000	1,500,000	Moderate	60	20	1–2	Fair to Good	Good	Moderate
C	3,000	1,000,000	Low	50	30	2–3	Fair	Good	High
D	0	500,000	Very High	40	5	3–4	Excellent	Poor	Low
^aReduction in expected frequency of disease among vaccinees.

Page
21

Front Matter (R1-R16)

1. Summary (1-18)

2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)

3. Overview of the Analytic Approach (30-43)

4. Comparison of Disease Burdens (44-62)

5. Predictions of Vaccine Development (63-75)

6. Assessing the Likely Utilization of New Vaccines (76-81)

7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)

8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)

9. Findings, Conclusions, and Recommendations (121-142)

Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)

Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)

Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)

Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)

Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)

Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)

Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)

Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)

Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)

Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)

Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)

Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)

Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)

Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)

Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)

Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)

Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)

Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)

Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)

Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)

Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)

Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)

Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)

Appendix F: Technical Notes (412-412)

Appendix G: Biographical Notes on Committee Members (413-417)

Appendix H: Additional Sources of Advice to the Committee (418-419)

Appendix I: Contents of Supplement to Volume II (420-420)

Appendix J: Preface to Volume I (421-422)

Appendix K: Contents to Volume I (423-423)

Index (424-432)